Ubix Therapeutics - CB Insights

Oct 8, 2024 · Funding, Valuation & Revenue. 4 Fundings. Ubix Therapeutics has raised $15.79M over 4 rounds.. Ubix Therapeutics's latest funding round was a Incubator/Accelerator for on …

CouponFollow Extension

$15.79
OFF

Ubix Therapeutics - CB Insights

4 weeks from now

Oct 8, 2024 · Funding, Valuation & Revenue. 4 Fundings. Ubix Therapeutics has raised $15.79M over 4 rounds.. Ubix Therapeutics's latest funding round was a Incubator/Accelerator for on …

cbinsights.com

$108
OFF

Yuhan Nabs Ubix Cancer Drug For ₩150B; YH-35995 Trial Cleared

4 weeks from now

Jul 1, 2024 · Yuhan Corp., of Seoul, South Korea, has inked a ₩150 billion (US$108.6 million) deal with Korean biotech Ubix Therapeutics Inc. to gain exclusive global rights to UBX-103, …

bioworld.com

FAQs about Ubix Therapeutics - CB Insights Coupon?

What is Debiopharm doing with UbiX Therapeutics?

Debiopharm has announced a collaboration with South Korean Ubix Therapeutics on a new research project using both companies’ proprietary technologies. ...

Who owns UbiX Therapeutics?

S.H.L. and J.H.R. are shareholders in Ubix Therapeutics and have ownership interests (including stock, patents, etc.). Patent PCT/KR2021/0 09287 is held on UBX-390. A patent application related to this work has been filed by Ubix Therapeutics, Inc. on behalf of the authors. ...

What does UbiX stand for?

Ubix Therapeutics, Inc. (UBIX) develops novel drugs based on Degraducer® platform technology. Degraducer® is a powerful next generation inhibitor technology that enables targeting of disease-related targets that were previously undruggable. ...

How effective is ubx-303-1?

UBX-303-1 has been designed to demonstrate efficacy by degrading over-expressed BTK proteins and has a different modality than other current BTK inhibitors. ...

Does ubx-303-1 have a good PK/PD profile?

UBX-303-1 showed excellent PK/PD profiles in the non-clinical studies conducted so far as well as superior anti-cancer efficacy in the C481S mutant Xenograft mouse model and in the wild type. ...

Is ubx-382 a promising treatment option for drug-resistant hematological cancer?

The in vivo efficacy of UBX-382 was outstanding in the TMD-8 and ibrutinib-resistant xenograft models, suggesting UBX-382 as a promising therapeutic option over BTK inhibitors for the treatment of drug-resistant hematological cancers. ...